Clinical Practices and Therapeutic Management of Mineral and Bone Disorders in Chronic Kidney Disease 4, 5 and 5D: The OCEANOS Study in Iran

Authors Information
Article Notes and Dates
To Cite : Nafar M, Rashid Farokhi F, Zeraati A A, Ossareh S, Atapour A, et al. Clinical Practices and Therapeutic Management of Mineral and Bone Disorders in Chronic Kidney Disease 4, 5 and 5D: The OCEANOS Study in Iran, Nephro-Urol Mon. 2018 ;10(1):e61632. doi: 10.5812/numonthly.61632.
Copyright: Copyright © 2018, Nephro-Urology Monthly. .
Abstract
1. Background
2. Methods
3. Results
4. Discussion
Footnotes
References
  • 1. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379(9811):165-80. doi: 10.1016/S0140-6736(11)60178-5. [PubMed: 21840587].
  • 2. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust MH, et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease-mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015;87(3):502-28. doi: 10.1038/ki.2014.425. [PubMed: 25651364].
  • 3. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607-17. doi: 10.1053/ajkd.1998.v31.pm9531176. [PubMed: 9531176].
  • 4. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis. 1999;33(2):287-93. doi: 10.1016/S0272-6386(99)70302-1. [PubMed: 10023640].
  • 5. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37(1 Suppl 2):S54-7. doi: 10.1053/ajkd.2001.20740. [PubMed: 11158862].
  • 6. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis. 1996;28(4):515-22. doi: 10.1016/S0272-6386(96)90461-8. [PubMed: 8840940].
  • 7. Andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013;84(3):622-3. doi: 10.1038/ki.2013.243. [PubMed: 23989362].
  • 8. Kidney Disease: Improving Global Outcomes CG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1-130. doi: 10.1038/ki.2009.188. [PubMed: 19644521].
  • 9. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1-201. doi: 10.1016/S0272-6386(03)00905-3. [PubMed: 14520607].
  • 10. Deger SM, Mutluay R, Derici U, Mandiralioglu F, Arinsoy T, Sindel S. Can calcium, phosphate, calcium phosphate product and intact parathyroid hormone levels be appropriately controlled in dialysis patients?. Med Princ Pract. 2011;20(1):85-9. doi: 10.1159/000319768. [PubMed: 21160221].
  • 11. Kim GH. Gaps between Global Guidelines and Local Practices in CKD-MBD. Electrolyte Blood Press. 2014;12(2):35-40. doi: 10.5049/EBP.2014.12.2.35. [PubMed: 25606042].
  • 12. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(5 Suppl 2):34-8. doi: 10.1016/S0272-6386(04)01103-5. [PubMed: 15486872].
  • 13. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388-96. doi: 10.1681/ASN.2008060609. [PubMed: 19092121].
  • 14. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268-77. doi: 10.1016/S0140-6736(13)60897-1. [PubMed: 23870817].
  • 15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-70. doi: 10.7326/0003-4819-130-6-199903160-00002. [PubMed: 10075613].
  • 16. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2. [PubMed: 15284307].
  • 17. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-8. [PubMed: 11562412].
  • 18. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, Rodriguez M, Aljama P. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46(1):68-77. doi: 10.1053/j.ajkd.2005.04.006. [PubMed: 15983959].
  • 19. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-40. doi: 10.1093/ndt/gfg414. [PubMed: 12937218].
  • 20. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66(6):2293-9. doi: 10.1111/j.1523-1755.2004.66015.x. [PubMed: 15569318].
  • 21. Goldsmith D, Covic A. Oral phosphate binders in CKD - is calcium the (only) answer?. Clin Nephrol. 2014;81(6):389-95. doi: 10.5414/CN108209. [PubMed: 25017668].
  • 22. London GM, Marchais SJ, Guerin AP, Boutouyrie P, Metivier F, de Vernejoul MC. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol. 2008;19(9):1827-35. doi: 10.1681/ASN.2007050622. [PubMed: 18480316].
  • 23. Pavan M, Ranganath R, Chaudhari AP, Upadhayaya KL, Mehta HJ. Practice pattern of chronic kidney disease-mineral and bone disorder (CKD-MBD) in hemodialysis patients in a tertiary care centre in India. Dial Traspl. 2012;33(4):110-4. doi: 10.1016/j.dialis.2011.12.001.
  • 24. Kong X, Zhang L, Zhang L, Chen N, Gu Y, Yu X, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study. BMC Nephrol. 2012;13:116. doi: 10.1186/1471-2369-13-116. [PubMed: 22994525].
  • 25. Robinson B, Fuller D, Zinsser D. The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: rationale and methods for an initiative to monitor the new US bundled dialysis payment system. Am J Kidney Dis. 2011.
  • 26. Jeloka T, Mali M, Jhamnani A, Konde S, Jadhav V. Are we overconcerned about secondary hyperparathyroidism and underestimating the more common secondary hypoparathyroidism in our dialysis patients?. J Assoc Physicians India. 2012;60:102-5. [PubMed: 22715556].
  • 27. Kim GH, Choi BS, Cha DR, Chee DH, Hwang E, Kim HW, et al. Serum calcium and phosphorus levels in patients undergoing maintenance hemodialysis: A multicentre study in Korea. Kidney Res Clin Pract. 2014;33(1):52-7. doi: 10.1016/j.krcp.2013.12.003. [PubMed: 26877950].
  • 28. Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran. Iran J Kidney Dis. 2007;1(1):25-8. [PubMed: 19357440].
  • 29. Patel L, Bernard LM, Elder GJ. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol. 2016;11(2):232-44. doi: 10.2215/CJN.06800615. [PubMed: 26668024].
  • 30. Rivera F, Sanchez de la Nieta MD, Echarri R, Anaya S, Carreno A, Vozmediano MC, et al. [CA-P control in haemodialysis and K/DOQI guidelines]. Nefrologia. 2006;26(3):351-7. [PubMed: 16892824].
  • 31. Wei M, Taskapan H, Esbaei K, Jassal SV, Bargman JM, Oreopoulos DG. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?. Int Urol Nephrol. 2006;38(3-4):739-43. doi: 10.1007/s11255-005-0083-x. [PubMed: 17160632].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By: